FDA approved revumenib for KMT2A-rearranged relapsed or refractory acute leukemia
The approval, dated November 15, 2024, covers adult and pediatric patients age 1 and older with relapsed or refractory disease carrying a KMT2A translocation.
FDA
4 stories
The approval, dated November 15, 2024, covers adult and pediatric patients age 1 and older with relapsed or refractory disease carrying a KMT2A translocation.
FDA
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Syndax posted $83.3 million in total third-quarter revenue and outlined a slate of fourth-quarter revumenib data readouts as Keith Goldan prepares to hand the CFO role to Aaron Ondrey.
SEC filing
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)